X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (82) 82
index medicus (70) 70
hematology (57) 57
oncology (57) 57
chemistry (49) 49
metallurgy (49) 49
organic chemistry (49) 49
human necessities (48) 48
hygiene (48) 48
medical or veterinary science (48) 48
preparations for medical, dental, or toilet purposes (48) 48
peptides (45) 45
male (38) 38
chronic myeloid leukemia (31) 31
aged (30) 30
chronic myelogenous leukemia (30) 30
female (29) 29
hemic and lymphatic diseases (26) 26
middle aged (25) 25
article (23) 23
cancer (23) 23
hematology, oncology and palliative medicine (23) 23
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (23) 23
antineoplastic agents - therapeutic use (22) 22
adult (21) 21
care and treatment (21) 21
chronic myeloid-leukemia (21) 21
leukemia (21) 21
animals (19) 19
protein kinase inhibitors - therapeutic use (19) 19
imatinib (18) 18
abridged index medicus (17) 17
nilotinib (17) 17
tyrosine kinase inhibitor (16) 16
bcr-abl (15) 15
dasatinib (15) 15
research (15) 15
therapy (15) 15
tyrosine kinase inhibitors (15) 15
chronic lymphocytic leukemia (14) 14
prognosis (14) 14
aged, 80 and over (13) 13
leukemia, lymphocytic, chronic, b-cell - drug therapy (13) 13
mice (13) 13
follow-up (12) 12
immunology (12) 12
mutation (12) 12
analysis (11) 11
leukemia, myelogenous, chronic, bcr-abl positive - genetics (11) 11
treatment outcome (11) 11
cml (10) 10
imatinib mesylate (10) 10
stem-cell transplantation (10) 10
biochemistry (9) 9
clinical trials as topic (9) 9
disease progression (9) 9
leukemia, lymphocytic, chronic, b-cell - pathology (9) 9
pyrimidines - therapeutic use (9) 9
review (9) 9
specific therapeutic activity of chemical compounds ormedicinal preparations (9) 9
t-lymphocytes - immunology (9) 9
transplantation (9) 9
young adult (9) 9
beer (8) 8
chronic-phase (8) 8
compositions thereof (8) 8
culture media (8) 8
dendritic cells (8) 8
enzymology (8) 8
leukemia, lymphocytic, chronic, b-cell - genetics (8) 8
leukemia, myelogenous, chronic, bcr-abl positive - therapy (8) 8
microbiology (8) 8
microorganisms or enzymes (8) 8
mutation or genetic engineering (8) 8
propagating, preserving or maintaining microorganisms (8) 8
quality of life (8) 8
quality-of-life (8) 8
spirits (8) 8
stem cells (8) 8
tyrosine (8) 8
vinegar (8) 8
wine (8) 8
benzamides (7) 7
bone-marrow-transplantation (7) 7
cd4-positive t-lymphocytes - immunology (7) 7
cell line (7) 7
cell line, tumor (7) 7
clinical trials (7) 7
cll (7) 7
cytotoxic t-lymphocytes (7) 7
drug therapy (7) 7
fermentation or enzyme-using processes to synthesise a desiredchemical compound or composition or to separate optical isomersfrom a racemic mixture (7) 7
gene expression (7) 7
genetic aspects (7) 7
hematopoietic stem cell transplantation (7) 7
heterocyclic compounds (7) 7
inflammation (7) 7
kinases (7) 7
leukemia, myelogenous, chronic, bcr-abl positive - pathology (7) 7
multiple-myeloma (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 02/2011, Volume 117, Issue 4, pp. 688 - 697
Tyrosine kinase inhibitor (TKI) treatment targeting breakpoint cluster region‐Abelson murine leukemia virus, the cause of chronic myeloid leukemia (CML), has... 
imatinib | dasatinib | tyrosine kinase inhibitor | nilotinib | intolerance
Journal Article
Fuel Processing Technology, ISSN 0378-3820, 08/2019, Volume 191, pp. 111 - 120
This work firstly provides a thorough insight into the effects of the operating conditions (catalyst loading, initial H pressure temperature, reaction time, H... 
Mo2C/CNF catalysts | Bio-fuels | Guaiacol | Hydrodeoxygenation | Bio-oil
Journal Article
Cancer, ISSN 0008-543X, 08/2017, Volume 123, Issue 15, pp. 2875 - 2880
In patients who have chronic‐phase chronic myeloid leukemia (CML) with the Philadelphia chromosome threonine to isoleucine mutation at codon 315, single‐agent... 
threonine to isoleucine mutation at codon 315 (T315I) | Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ ALL) | ponatinib | allogeneic stem cell transplantation (allo‐SCT) | chronic myeloid leukemia (CML) | Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) | allogeneic stem cell transplantation (allo-SCT) | RESISTANT | ONCOLOGY | ACUTE LYMPHOBLASTIC-LEUKEMIA | MARGINAL STRUCTURAL MODELS | PHASE-2 | INHIBITORS | Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL) | CHRONIC MYELOID-LEUKEMIA | Multivariate Analysis | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Antineoplastic Agents - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy | Transplantation, Homologous | Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy | Adult | Female | Retrospective Studies | Imidazoles - therapeutic use | Philadelphia Chromosome | Pyridazines - therapeutic use | Kaplan-Meier Estimate | Proportional Hazards Models | Survival Rate | Treatment Outcome | Blast Crisis - therapy | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Stem Cell Transplantation - methods | Aged | Blast Crisis - genetics | Mutation | Chemotherapy | Usage | Care and treatment | Gene mutations | Stem cells | Transplantation | Chronic myeloid leukemia | Diagnosis | Research | Cancer | Intervention | Transplants & implants | Leukemia | Bone marrow transplantation | Stem cell transplantation | Blast | Confidence intervals | Bone marrow | Chromosomes | Age | Isoleucine | Cell survival | Acute lymphatic leukemia | Threonine | Myeloid leukemia | Hazards | Crises | Lymphatic leukemia | Patients | Survival | Philadelphia chromosome | Original
Journal Article
American Journal of Hematology, ISSN 0361-8609, 07/2015, Volume 90, Issue 7, pp. 602 - 607
Peptide vaccines are capable of eliciting immune responses targeting tumor‐associated antigens such as the Wilms’ Tumor 1 (WT1) antigen, often overexpressed in... 
ONCOPROTEIN | CELL RESPONSES | MESSENGER-RNA | MEMORY | ACUTE MYELOID-LEUKEMIA | MUTATIONS | HEMATOLOGY | CANCER | CYTOTOXIC T-LYMPHOCYTES | TUMOR GENE WT1 | INTERNATIONAL WORKING GROUP | Hypersensitivity, Delayed - pathology | Humans | Vaccination | Male | Leukemia, Myeloid, Acute - immunology | Hypersensitivity, Delayed - immunology | Peptides - administration & dosage | Cancer Vaccines - therapeutic use | Myelodysplastic Syndromes - therapy | WT1 Proteins - chemistry | Immunization, Secondary | Peptides - chemical synthesis | Karyotyping | WT1 Proteins - immunology | Aged, 80 and over | Female | Hypersensitivity, Delayed - diagnosis | WT1 Proteins - genetics | Leukemia, Myeloid, Acute - therapy | Gene Expression | Granulocyte-Macrophage Colony-Stimulating Factor - administration & dosage | Vaccines, Subunit | Leukemia, Myeloid, Acute - pathology | Peptides - immunology | Immunologic Factors - administration & dosage | Remission Induction | Recombinant Proteins - administration & dosage | Leukemia, Myeloid, Acute - mortality | Pilot Projects | Interferon-gamma - immunology | Myelodysplastic Syndromes - mortality | Survival Analysis | Aged | Myelodysplastic Syndromes - pathology | Interferon-gamma - biosynthesis | Myelodysplastic Syndromes - immunology | Peptides | T cells | Analysis | Leukemia | Index Medicus
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 06/2014, Volume 124, Issue 6, pp. 2585 - 2598
Activation of the ER stress response is associated with malignant progression of B cell chronic lymphocytic leukemia (CLL). We developed a murine CLL model... 
SELECTIVE-INHIBITION | MULTIPLE-MYELOMA | MEDICINE, RESEARCH & EXPERIMENTAL | IN-VITRO | UNFOLDED PROTEIN RESPONSE | TCL1 | MESSENGER-RNA | TRANSGENIC MOUSE | CHRONIC LYMPHOCYTIC-LEUKEMIA | ENDOPLASMIC-RETICULUM | TARGETING BTK | Endoribonucleases - genetics | Apoptosis - drug effects | Humans | Transcription Factors - deficiency | Endoribonucleases - antagonists & inhibitors | DNA-Binding Proteins - deficiency | X-Box Binding Protein 1 | DNA-Binding Proteins - metabolism | Enzyme Inhibitors - chemistry | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Protein-Serine-Threonine Kinases - metabolism | Pyrazoles - pharmacology | Cell Survival - drug effects | DNA-Binding Proteins - antagonists & inhibitors | Endoplasmic Reticulum Stress - drug effects | Endoribonucleases - metabolism | Enzyme Inhibitors - pharmacology | Protein-Serine-Threonine Kinases - genetics | Transcription Factors - antagonists & inhibitors | Pyrimidines - pharmacology | Transcription Factors - genetics | DNA-Binding Proteins - genetics | Regulatory Factor X Transcription Factors | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Mice, Knockout | Transcription Factors - metabolism | Animals | Signal Transduction - drug effects | Leukemia, Lymphocytic, Chronic, B-Cell - metabolism | Cell Line, Tumor | Mice | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Care and treatment | Lymphocytic leukemia | Cancer cells | Development and progression | Genetic aspects | Cellular signal transduction | Gene expression | Leukemia | Rodents | Phenols | Kinases | Stress response | Drug dosages | Immune system | Apoptosis
Journal Article
Journal of Leukocyte Biology, ISSN 0741-5400, 08/2017, Volume 102, Issue 2, pp. 475 - 486
Journal Article
P and T, ISSN 1052-1372, 2014, Volume 39, Issue 7, pp. 483 - 519
Ibrutinib (Imbruvica): a novel targeted therapy for chronic lymphocytic leukemia. 
Departments
Journal Article
Biologics: Targets and Therapy, ISSN 1177-5475, 02/2016, Volume 10, pp. 23 - 31
Examines the role of nilotinib, an oral second-generation tyrosine kinase inhibitor (TKI), in the treatment of Philadelphia positive chronic myelogenous... 
Nilotinib | Chronic myelogenous leukemia | Tyrosine kinase inhibitor | Inhibitors | Treatment | Chronic myeloid leukemia | Protein-tyrosine kinase | Leukemia | Care and treatment | Analysis | Research | Chromosomes | Quality of life | Transplants & implants | FDA approval | Kinases | Patients | Cancer therapies | Blood | Proteins | Gene amplification | Stem cells | Diabetes | Age
Journal Article
Future Oncology, ISSN 1479-6694, 01/2019, Volume 15, Issue 3, pp. 257 - 269
Philadelphia chromosome, reciprocal translocation between chromosome 9 and 22, leading to a constitutively active fusion protein BCR-ABL1 is the common feature... 
chronic myeloid leukemia | ponatinib | CML | Philadelphia positive ALL | ADULT PATIENTS | LONG-TERM OUTCOMES | FOLLOW-UP | COMPOUND MUTATIONS | PHASE-II | DASATINIB | HYPER-CVAD | ONCOLOGY | IMATINIB | TYROSINE KINASE INHIBITOR | T315I MUTANT
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 3287 - 3287
Abstract Background: Advances in molecular genetics have changed the risk stratification and treatment of patients with Chronic Lymphocytic Leukemia (CLL).... 
Journal Article
Anticancer Research, ISSN 0250-7005, 12/2015, Volume 35, Issue 12, pp. 6355 - 6364
With the success of tyrosine kinase inhibitor (TKI) therapy for the treatment of patients with chronic myeloid leukemia (CML), CML is now treated as a chronic... 
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 4967 - 4967
Journal Article
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14_Supplement, pp. 545 - 545
INTRODUCTION: TGR-1202 is a novel, next-generation PI3K inhibitor presenting significant structural and pharmacological differences from prior small-molecule... 
Journal Article
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. 545 - 545
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.